Related Experiment Video
Updated: Jul 31, 2026
Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
Cost effectiveness of risk reduction: the managed care perspective
1United HealthCare Services, Inc., Itasca, Illinois 60143-1299, USA.
Insights
Reducing hospitalizations and optimizing drug therapy for coronary artery disease (CAD) can lower healthcare costs. Improving adherence to evidence-based treatments, like lipid-lowering agents, is crucial for cost-effective CAD management.
Area of Science:
- Health Economics
- Cardiovascular Medicine
- Healthcare Management
Background:
- Coronary artery disease (CAD) incurs significant annual healthcare expenditures, estimated at nearly $140 billion.
- Opportunities for cost savings exist by addressing both overutilization and underutilization of healthcare services for CAD patients.
- Variability in prescribing practices impacts the cost-effectiveness of CAD therapies.
Purpose of the Study:
- To identify strategies for reducing healthcare costs associated with coronary artery disease.
- To emphasize the role of precise diagnosis, prevention, and early intervention in managing CAD.
- To highlight the cost-effectiveness of pharmacologic interventions in CAD management.
Main Methods:
- Analysis of healthcare expenditure data related to coronary artery disease.
- Review of current treatment guidelines and prescribing practices for CAD.
- Evaluation of the cost-effectiveness of specific therapeutic agents, such as lipid-lowering drugs.
Main Results:
- Reducing hospitalization rates for CAD patients presents a major opportunity for cost savings.
- Underutilization of proven therapies, including lipid-lowering agents (used in only 25% of CAD patients) and post-myocardial infarction medications, contributes to higher costs.
- Effective drug therapies can yield substantial savings by decreasing the need for further medical care.
Conclusions:
- Optimizing the diagnosis, prevention, and early intervention strategies for CAD is essential for cost reduction.
- Improving the utilization of cost-effective medications, particularly for secondary prevention in CAD, can significantly reduce overall healthcare expenditures.
- Standardizing prescribing practices is key to maximizing the cost-effectiveness of CAD risk reduction therapies.
Abstract:
Coronary artery disease (CAD) is responsible for nearly $140 billion in healthcare expenditures each year. A major opportunity for cost savings lies in reducing the overutilization of hospitalization for CAD patients. This goal may be accomplished through several strategies: more precise diagnosis of CAD, primary and secondary prevention, and early intervention. Underutilization of health services and treatment also contributes to higher overall medical costs. Even though drug therapy incurs costs, effective medications can produce substantial savings by reducing the need for additional medical care. For example, lipid-lowering agents are particularly cost effective when used as secondary prevention in patients with CAD; however, only 25% of patients receive such therapy. Likewise, not all patients who suffer acute myocardial infarction are treated with any of the agents proven to reduce the risk of subsequent adverse cardiovascular events. The elimination of variability in prescribing practices should help optimize the cost effectiveness of therapies aimed at reducing CAD risk.
Related Concept Videos
01:18Introduction To Health Care Delivery System
The Institute of Medicine (IOM) advocates for a patient-centered, effective, safe, timely, equitable, and effective healthcare system. The National Priorities...
01:26Methods Of Healthcare Delivery System
Managed Care System:
The managed care system is designed to control the cost while maintaining the quality of care. The patient's care from admission to discharge is planned by the primary care provider or the case manager, also known as the gatekeeper. In a managed care system, the number of care providers is limited...
01:15Methods of Documentation VI: Case Management Model
For example, a patient with a chronic illness...
01:30Health Information Technology and Healthcare Information System
Health Information Technology, commonly called HIT, integrates advanced information systems and technology in healthcare settings. Its primary functions include:
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:12Relative Risk